Does Medicaid Cover GLP-1 Medications in 2026?
Introduction
Medicaid coverage of GLP-1 medications in 2026 depends entirely on your state and your diagnosis. For type 2 diabetes, almost every state covers Ozempic®, Trulicity®, and Mounjaro® with prior authorization. For obesity, only 16 state Medicaid programs cover Wegovy® and 14 cover Zepbound® as of Q1 2026, per KFF formulary tracking.
The reason is structural. Federal law (Social Security Act Section 1927) lets states exclude “agents when used for weight loss.” Diabetes is medically required coverage. Obesity is optional. This split drives almost every patient outcome.
This article walks through what is covered, what is not, and where the line falls in each state. It also covers prior authorization requirements and what to do if you live in a state that excludes anti-obesity drugs.
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.
Which GLP-1 Medications Does Medicaid Cover for Diabetes?
Medicaid covers Ozempic, Mounjaro, Trulicity, Rybelsus®, and Victoza® for type 2 diabetes in all 50 states. Coverage requires prior authorization in most states, with criteria including A1c above target, documented metformin trial, and sometimes a SGLT2 inhibitor trial first.
Quick Answer: Diabetes GLP-1s (Ozempic, Mounjaro, Trulicity) are covered in nearly all 50 state Medicaid programs with PA
The SUSTAIN program (Ozempic), SURPASS program (Mounjaro), and AWARD trials (Trulicity) provide the clinical basis. These trials showed A1c reductions of 1.0-2.5% and modest weight loss as a secondary endpoint. Medicaid programs typically approve based on diabetes management, not weight loss.
Step therapy is standard. Most states require a trial of metformin first, then either an SGLT2 inhibitor or a sulfonylurea, before approving a GLP-1. This adds time to access but is straightforward to document.
Which GLP-1 Medications Does Medicaid Cover for Obesity?
Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are the FDA-approved obesity GLP-1s. As of Q1 2026, 16 state Medicaid programs covered Wegovy and 14 covered Zepbound for obesity per KFF data. Coverage requires BMI 30+, or BMI 27+ with comorbidity, plus documented lifestyle intervention.
Saxenda® (liraglutide) is also approved for obesity and covered by some state Medicaid programs. It is older and less effective than Wegovy or Zepbound, but it is sometimes the only obesity GLP-1 on a state’s preferred drug list.
The Wegovy cardiovascular indication, added in March 2024 based on the SELECT trial (Lincoff et al. 2023 NEJM), changes some state coverage decisions. States that exclude weight-loss drugs may still cover Wegovy for cardiovascular risk reduction in patients with established CV disease.
Which States Cover Wegovy Under Medicaid in 2026?
States with the broadest Medicaid coverage for Wegovy as of Q1 2026 include California, Pennsylvania, Michigan, Delaware, Massachusetts, Minnesota, New Mexico, Rhode Island, and Virginia. Each requires prior authorization but does not categorically exclude weight-loss agents.
Coverage criteria in these states typically include BMI 30+ or BMI 27+ with at least one comorbidity (type 2 diabetes, hypertension, hyperlipidemia, OSA, or established CV disease), documented six-month lifestyle attempt, and sometimes step therapy through phentermine or orlistat.
States with active expansion discussions in 2025-2026 included North Carolina (pilot program for state employees in 2024), Connecticut, and Maryland. North Carolina’s pilot was paused mid-2024 due to cost overruns.
Which States Cover Zepbound Under Medicaid in 2026?
States covering Zepbound under Medicaid for obesity as of Q1 2026 include California, Massachusetts, Pennsylvania, Michigan, Minnesota, Delaware, and New Mexico. The list is smaller than Wegovy’s because Zepbound is newer and many state PDLs have not added it yet.
The SURMOUNT-OSA indication (FDA-approved December 2024) created additional coverage paths. State Medicaid programs that exclude obesity drugs may still cover Zepbound when prescribed for moderate-to-severe obstructive sleep apnea in patients with obesity.
A sleep study showing AHI of 15+ is the documentation threshold. SURMOUNT-OSA showed tirzepatide reduced AHI by roughly 27-30 events per hour over 52 weeks, providing the clinical basis for the indication.
Which States Exclude Weight-loss Drugs From Medicaid?
Texas, Florida, Georgia, North Carolina, Tennessee, Alabama, Mississippi, Louisiana, and Arkansas categorically excluded anti-obesity medications from Medicaid as of Q1 2026. In these states, no PA argument on the weight-loss indication will succeed.
The exclusions are based on Section 1927 of the Social Security Act, which explicitly allows states to exclude weight-loss drugs. Cost is the driving factor. A 2024 Congressional Budget Office estimate put the 10-year federal cost of covering GLP-1s for all eligible Medicaid enrollees at roughly $35-50 billion.
In exclusion states, the only path to GLP-1 coverage is reframing the prescription around a separate FDA indication. Cardiovascular risk reduction (Wegovy), type 2 diabetes (Ozempic/Mounjaro), or OSA (Zepbound) can all unlock coverage that obesity alone cannot.
What Are the Prior Authorization Requirements?
Medicaid PA requirements for GLP-1s typically include BMI documentation, A1c values for diabetes indications, comorbidity ICD-10 codes, prior medication trials, and documented lifestyle intervention. The exact list varies by state.
For diabetes GLP-1s (Ozempic, Mounjaro), PA usually requires A1c above 7.0%, prior metformin trial (or contraindication), and sometimes a second-line agent trial. Approval terms run 6-12 months and require A1c improvement to renew.
For obesity GLP-1s in states that cover them, PA requires BMI 30+ or 27+ with comorbidity, six-month lifestyle attempt documented in chart notes, and sometimes prior phentermine or orlistat trial. Approval is usually 12 months with weight-loss progress required to renew.
Key Takeaway: States with broadest obesity coverage: CA, PA, MI, DE, MA, MN, NM
What Does Coverage Actually Cost the Patient?
Medicaid copays for covered medications are typically $0-4 per prescription. There is no deductible. Out-of-pocket cost is functionally zero when coverage is approved.
This is the entire reason Medicaid coverage matters so much. Brand Wegovy retail is roughly $1,350 per month. Brand Zepbound is around $1,060. Cash-pay is prohibitive for most Medicaid-eligible patients. Coverage versus no coverage is the difference between accessible therapy and no therapy.
What If I Live in an Exclusion State and Want a GLP-1?
If you live in a state that excludes weight-loss drugs from Medicaid and you do not have diabetes, your real options are limited. You can pursue the CV or OSA indications if applicable, pay cash for brand GLP-1s, or use compounded semaglutide or tirzepatide through a 503A pharmacy.
Compounded options run substantially below brand retail. TrimRx offers a free assessment quiz that screens for eligibility and connects qualifying patients with licensed providers for a personalized treatment plan including compounded semaglutide or tirzepatide.
Brand GLP-1 manufacturers also offer patient assistance programs. Novo Nordisk’s NovoCare and Eli Lilly’s LillyDirect can sometimes provide medication at reduced cost for patients without coverage, but eligibility criteria are tight.
How Do State Medicaid Budgets Affect GLP-1 Coverage Decisions?
State Medicaid programs operate within annual budgets, and GLP-1 coverage is one of the most consequential cost drivers in recent years. A single-state actuarial analysis from 2024 estimated that covering Wegovy and Zepbound for all eligible Medicaid enrollees would add $200-400 million per year in pharmacy spending in mid-sized states.
This cost driver is why so many states maintain categorical exclusions. North Carolina’s 2024 pilot program for state employees and dependents was paused mid-year after costs ran above budget projections. The pilot showed that real-world utilization exceeded the actuarial estimates.
For patients, the implication is that state coverage decisions are partly political and partly fiscal. Coverage expansion tends to follow legislative cycles. Knowing your state legislative calendar can help time advocacy or appeal efforts.
What Recent Clinical Trial Data Has Affected Medicaid Policy?
The SELECT trial (Lincoff et al. 2023 NEJM) showing Wegovy’s 20% reduction in major adverse cardiovascular events has influenced Medicaid coverage discussions. The cardiovascular benefit reframes Wegovy from a weight-loss drug to a cardiovascular drug, and several state Medicaid programs have considered separate PA pathways for the CV indication.
The SURMOUNT-OSA trial (published 2024) led to Zepbound’s December 2024 FDA approval for moderate-to-severe OSA. Some state Medicaid programs added OSA coverage paths in 2025-2026, providing access in states that exclude obesity drugs.
The FLOW trial (Perkovic et al. 2024 NEJM) showed semaglutide reduced kidney and cardiovascular death by 24% in patients with type 2 diabetes and chronic kidney disease. This indication is not yet driving Medicaid coverage changes but is being studied for inclusion in future policy.
Bottom line: Federal Medicaid law allows exclusion of weight-loss agents (Section 1927)
FAQ
Does Medicaid Cover Ozempic for Weight Loss?
No. Ozempic is FDA-approved only for type 2 diabetes. Medicaid will cover Ozempic for diabetes but not for off-label weight-loss use.
Does Medicaid Require STEP Therapy for GLP-1s?
Yes in most states. Diabetes GLP-1s usually require metformin first. Obesity GLP-1s often require phentermine or orlistat first.
How Long Does Medicaid PA Approval Last for GLP-1s?
Usually 6-12 months. Renewal requires documented clinical response (A1c improvement for diabetes, weight loss for obesity).
Can I Appeal a Medicaid GLP-1 Denial?
Yes. Federal law gives you 60-90 days to file an internal redetermination, with a fair hearing as the second step.
Does Medicaid Cover Compounded GLP-1s?
No. All state Medicaid programs exclude compounded medications from coverage as of 2026.
What Is the Difference Between Medicaid and Medicare for GLP-1 Coverage?
Medicare Part D has a federal law preventing coverage of weight-loss drugs across all plans. Medicaid is state-by-state, so coverage exists in some states for obesity. Both cover diabetes GLP-1s.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.
Related Articles
Transforming Lives, One Step at a Time
Keep reading
GLP-1 Medications for Men Over 40: Testosterone, Metabolism, and Results
Weight loss for men over 40 operates under a different set of biological conditions than it did in your 20s or 30s, and GLP-1…
Long-Term Weight Loss Success on GLP-1: Habits That Actually Stick
GLP-1 medications are among the most effective weight loss tools ever developed, but they don’t produce identical long-term outcomes for everyone who takes them….
GLP-1 Maintenance vs Active Weight Loss: How Dosing Strategy Changes
Most of the conversation around GLP-1 medications focuses on the active weight loss phase: how fast results come, what side effects to expect, and…
